Four presentations at AHA, including one from the Framingham Heart Study, link PAT signal with several cardio-vascular conditions and risk factors as
technology gains broader acceptance
ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Itamar Medical announced confirmation of PAT technology by several prestigious research groups. In light of scientific confirmation of PAT technology, Itamar Medical will now promote clinical use in the medical community for the prevention of cardiovascular disease.
Presentation of several research works at the American Heart Association's Scientific Sessions, including one by the Framingham Heart Study, as well as numerous other recently published studies, support the emerging of the Endo- PAT as a significant tool in the prevention and management of cardiovascular disease.
Based on the new studies, combined with earlier numerous successful trials of the Endo-PAT at the Mayo Clinic, Harvard University and other academic medical centers, Itamar Medical is now ready to make Endo-PAT Technology available to clinicians beyond the research environment and into the general medical community.
The Endo-PAT, developed by Itamar Medical, is the only FDA approved non- invasive device that reliably detects a pathology called endothelial dysfunction. The condition refers to an impairment of the endothelial layer, which is the inner tissue lining of the blood vessels and is emerging as a key precursor for the development of atherosclerosis -- a major component in cardiac disease, the nation's number one killer.
The non-invasive Endo-PAT device, based on PAT technology, measures
subtle but significant vaso-motion changes through a small thimble-like
probe placed over a person's index finger. Tests administered with the
Endo-PAT provide clinicians and researchers an effective tool for the
detection of endothelial dysfunction. Early detection has the potential to
reduce the medical and cost burden of cardi
|SOURCE Itamar Medical Ltd.|
Copyright©2007 PR Newswire.
All rights reserved